Search - tctmd.com

Displaying 261 - 280 of 1109

Sort: Relevancy | Date

Presentation TCT 2015

Italy Presents: A Case Demonstrating the Diagnostic Workup in Nonobstructive Coronary Artery Disease

Presenter: Morton J. Kern, Jan J. Piek, Giampaolo Niccoli

October 12, 2015

Presentation TCT 2015

Spain Presents: A Case of iFR-FFR to Guide Coronary Revascularization in Multivessel Disease

Presenter: Morton J. Kern, Jan J. Piek, Javier Escaned

October 12, 2015

Presentation TCT 2015

The United Kingdom Presents: A Case of iFR for Evaluation of Serial Stenosis Using Pullback

Presenter: Morton J. Kern, Jan J. Piek, Justin E. Davies

October 12, 2015

News Industry News

STENTYS Sirolimus-Eluting Stent Confirms Best-in-Class Performance at 3 Years(1)

October 12, 2015

News Industry News

Follow-up imaging data from APPOSITION IV study to be presented at TCT conference in San Francisco

October 12, 2015

News Conference News TCT 2015

Mortality Increasing in Elderly PCI Patients

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

Presentation TCT 2015

How to Assess the Quality of Evidence From Peer-Reviewed Manuscripts: The Statistical Reviewers Vantage Point

Presenter: Robert A. Harrington, Pascal Vranckx, Jan Tijssen

October 11, 2015

Presentation TCT 2015

Bayesian Statistics: Can They Be Trusted (or Understood)?!

Presenter: Stuart J. Pocock, Jan Tijssen, Sanjay Kaul

October 11, 2015

Presentation TCT 2015

Meta-analysis (Standard and Network): The Good, the Bad, and the Ugly

Presenter: Stuart J. Pocock, Jan Tijssen, Somjot S. Brar

October 11, 2015

Presentation TCT 2015

Composite Endpoints/Primary Endpoints/Weighted Endpoints/Patient-Reported Endpoints: How to Choose the Right Endpoint

Presenter: Stuart J. Pocock, Jan Tijssen

October 11, 2015

Presentation TCT 2015

Strategy Trials vs Device/Drug Comparisons: Important Considerations

Presenter: Stuart J. Pocock, Jan Tijssen, David J. Cohen

October 11, 2015

Presentation TCT 2015

Propensity-Matched Analysis: Advantages and Pitfalls (TRANSLATE and PROMETHEUS)

Presenter: Stuart J. Pocock, Jan Tijssen, Usman Baber

October 11, 2015

Presentation TCT 2015

Subgroup Analyses: How Useful or Harmful Are They?

Presenter: Stuart J. Pocock, Jan Tijssen, Darrel P. Francis

October 11, 2015

Presentation TCT 2015

Observational vs Randomized Trials: Strengths and Weaknesses (With Case Examples)

Presenter: Stuart J. Pocock, Jan Tijssen, John L. Petersen

October 11, 2015

News Daily News

Transradial PCI May Attenuate Bivalirudin Benefits

Todd Neale

October 05, 2015

News Daily News

In the Early Days of TAVR, No Mortality Penalty for Patients Treated Outside of Trial Centers

October 01, 2015

News Daily News

Public Reporting of PCI Mortality Tied to Fewer High-Risk Cases But Better Outcomes

September 24, 2015

News Daily News

RenalGuard Protects TAVR Patients Against AKI Better Than Does Standard Saline

September 22, 2015

News Industry News

CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

September 21, 2015

Advertisement

Italy Presents: A Case Demonstrating the Diagnostic Workup in Nonobstructive Coronary Artery Disease

Spain Presents: A Case of iFR-FFR to Guide Coronary Revascularization in Multivessel Disease

The United Kingdom Presents: A Case of iFR for Evaluation of Serial Stenosis Using Pullback

STENTYS Sirolimus-Eluting Stent Confirms Best-in-Class Performance at 3 Years(1)

Follow-up imaging data from APPOSITION IV study to be presented at TCT conference in San Francisco

Mortality Increasing in Elderly PCI Patients

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

How to Assess the Quality of Evidence From Peer-Reviewed Manuscripts: The Statistical Reviewers Vantage Point

Bayesian Statistics: Can They Be Trusted (or Understood)?!

Meta-analysis (Standard and Network): The Good, the Bad, and the Ugly

Composite Endpoints/Primary Endpoints/Weighted Endpoints/Patient-Reported Endpoints: How to Choose the Right Endpoint

Strategy Trials vs Device/Drug Comparisons: Important Considerations

Propensity-Matched Analysis: Advantages and Pitfalls (TRANSLATE and PROMETHEUS)

Subgroup Analyses: How Useful or Harmful Are They?

Observational vs Randomized Trials: Strengths and Weaknesses (With Case Examples)

Transradial PCI May Attenuate Bivalirudin Benefits

In the Early Days of TAVR, No Mortality Penalty for Patients Treated Outside of Trial Centers

Public Reporting of PCI Mortality Tied to Fewer High-Risk Cases But Better Outcomes

RenalGuard Protects TAVR Patients Against AKI Better Than Does Standard Saline

CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content